Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 5Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 54Other hematologic neoplasm 28Breast 27Gastrointestinal 24Thoracic 23Lymphoid 21Genitourinary 14Gynecologic 11Myeloid 10CNS 5Plasma cell 4Head & Neck 4NET 3Endocrine 3Tumor-Agnostic 2Sarcoma 2Dermatologic 2Classical hematology 2Other 1

Conditions

Neurofibromatosis 1 1Neuroblastoma 1Leukemia, Myelomonocytic, Juvenile 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Temozolomide 79Magnetic Resonance Spectroscopy 68Specimen Handling 45Radiotherapy 42Bevacizumab 29Radiosurgery 27Cyclophosphamide 27Radiation 20pembrolizumab 19Blood Specimen Collection 19fludarabine 16Nivolumab 16Irinotecan 15Carboplatin 13Biopsy 13Etoposide 12Vincristine 11Pemetrexed 11Lomustine 11dinutuximab 9Surgical Procedures, Operative 9trametinib 8abemaciclib 8Ipilimumab 8naxitamab 7fluciclovine F-18 7Watchful Waiting 7Topotecan 7Proton Therapy 7Magnetic Resonance Imaging 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Injections × CNS × Clear all
NCT07589257 2026-05-15

A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma

Guangzhou Virotech Pharmaceutical Co., Ltd.

Phase 2 Recruiting
10 enrolled
CNS

Diffuse Intrinsic Pontine Glioma

NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1/2 Recruiting
58 enrolled
CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT06482905 2026-03-24

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

Tcelltech Inc.

Phase 1 Recruiting
52 enrolled
CNS

Glioma

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Sun Yat-sen University

Phase 2 Recruiting
120 enrolled
CNS

Neuroblastoma

NCT06598787 2025-05-07

A Study of BL-B01D1 in Patients With Recurrent Glioblastoma

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
20 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡